IACP and the New Jersey Association Meet with Legislator
To date, only the New Jersey legislature has two actual bills affecting compounding in the current legislative session. Assembly Bill 3453, as introduced by Health Committee Chairman Herbert Conaway, M.D.
, last November, would require compounding pharmacies that engage in the preparation of compounded medications in New Jersey to be credited by the Pharmacy Compounding Accreditation Board (PCAB) and furnish evidence to the State board of the pharmacy accreditation no later than one year after the effective date of the bill. Click here
to view the full text of the bill. A companion bill also has been introduced in the New Jersey Senate. Click here
for the Senate bill's full text.
On January 15, 2013, representatives from IACP along with the staff and leadership of the New Jersey Pharmacists Association (NJPhA), and the Garden State Pharmacists Association met with Chairman Conaway to update him and his staff on the NECC tragedy. IACP Executive Vice President & CEO David G. Miller, RPh
, explained that while IACP supports voluntary accreditation based upon an individual practice's professional and business decision making, the Academy is opposed to mandatory accreditation. As written AB 3453 could unintentionally restrict access to compounded medications for New Jersey patients because many small compounders, community pharmacists that compound a few preparations a month, and even institutional practices that serve health-systems and skilled nursing facilities may be unable to obtain accreditation through PCAB or already have accreditation status with other accrediting bodies.
NJPhA CEO Elise Barry
and the NJPhA Government Affairs Legislative Counsel continue to distribute information to New Jersey pharmacists about evolving state compounding actions. The organization works closely with the state legislature and regulatory bodies, including the Board of Pharmacy, to represent the interests of all practitioners within the state. Thanks to their efforts and collaboration with IACP, Chairman Conaway is interested in working with the compounding community to refine the bill's language to balance the need to protect patients without unduly burdening pharmacy business and practice. The bill will most likely have its first hearing in the April 2013 timeframe, and the two organizations will continue to work together to recommend amendatory language. IACP will keep you apprived of developments.